Abdelhafez Mohammad, Nasereddin Abedelmajeed, Shamma Omar Abu, Abed Rajaa, Sinnokrot Raghida, Marof Omar, Heif Tariq, Erekat Zaid, Al-Jawabreh Amer, Ereqat Suheir
Department of Internal Medicine, Faculty of Medicine, Al-Quds University, Abu Deis, East Jerusalem, State of Palestine.
Biochemistry and Molecular Biology Department, Faculty of Medicine, Al-Quds University, Abu Deis, East Jerusalem, State of Palestine.
Interdiscip Perspect Infect Dis. 2023 Sep 16;2023:9551163. doi: 10.1155/2023/9551163. eCollection 2023.
The clinical course and severity of COVID-19 vary among patients. This study aimed to investigate the potential correlation between the gene polymorphisms of the interferon receptor () rs2236757 and oligoadenylate synthetase 3 () rs10735079 with the risk of COVID-19 infection and its severity among Palestinian patients. The study was conducted between April and May 2021 on 154 participants who were divided into three groups: the control group (RT-PCR-negative, = 52), the community cases group (RT-PCR-positive, = 70), and the critically ill cases (ICU group; = 32). The genotyping of the investigated polymorphisms was performed using amplicon-based next-generation sequencing. The genotypes distribution for the rs2236757 was significantly different among the study groups ( = 0.001), while no statistically significant differences were found in the distribution of genotypes for the rs10735079 ( = 0.091). Logistic regression analysis adjusted for possible confounding factors revealed a significant association between the risk allele rs2236757A and critical COVID-19 illness ( < 0.025). Among all patients, those who carried the rs2236757GA were more likely to have a sore throat (OR, 2.52 (95% CI 1.02-6.24); = 0.011); the presence of the risk allele rs2236757A was associated with an increased risk to dyspnea (OR, 4.70 (95% CI 1.80-12.27); < 0.001), while the rs10735079A carriers were less likely to develop muscle aches (OR, 0.34 (95% CI 0.13-0.88); = 0.0248) and sore throat (OR, 0.17 (95% CI 0.05-0.55); < 0.001). In conclusion, our results revealed that the rs2236757A variant was associated with critical COVID-19 illness and dyspnea, whereas the rs10735079A variant was protective for muscle aches and sore throat.
新型冠状病毒肺炎（COVID-19）患者的临床病程和严重程度各不相同。本研究旨在调查干扰素受体（）rs2236757和寡腺苷酸合成酶3（）rs10735079的基因多态性与巴勒斯坦患者感染COVID-19的风险及其严重程度之间的潜在相关性。该研究于2021年4月至5月对154名参与者进行，他们被分为三组：对照组（逆转录聚合酶链反应阴性，=52）、社区病例组（逆转录聚合酶链反应阳性，=70）和危重症病例组（重症监护病房组；=32）。使用基于扩增子的下一代测序技术对所研究的多态性进行基因分型。rs2236757的基因型分布在研究组之间存在显著差异（=0.001），而rs10735079的基因型分布没有统计学上的显著差异（=0.091）。对可能的混杂因素进行校正的逻辑回归分析显示，风险等位基因rs2236757A与重症COVID-19疾病之间存在显著关联（<0.025）。在所有患者中，携带rs2236757GA的患者更易出现喉咙痛（比值比，2.52（95%置信区间1.02-6.24）；=0.011）；风险等位基因rs2236757A的存在与呼吸困难风险增加相关（比值比，4.70（95%置信区间1.80-12.27）；<0.001），而rs10735079A携带者出现肌肉疼痛（比值比，0.34（95%置信区间0.13-0.88）；=0.0248）和喉咙痛（比值比，0.17（95%置信区间0.05-0.55）；<0.001）的可能性较小。总之，我们的结果显示，rs2236757A变异与重症COVID-19疾病和呼吸困难相关，而rs10735079A变异对肌肉疼痛和喉咙痛具有保护作用。
